These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20414010)

  • 41. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
    Experts in Chronic Myeloid Leukemia
    Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pricing Cancer Drugs: When Does Pricing Become Profiteering?
    Kushnick HL
    AMA J Ethics; 2015 Aug; 17(8):750-3. PubMed ID: 26270874
    [No Abstract]   [Full Text] [Related]  

  • 43. [Economic burden of cancer patients undergoing oral chemotherapy].
    Koinuma N
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1230-3. PubMed ID: 20647704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Makers of anticancer drugs are "profiteering," say 100 specialists from around the world.
    Laurance J
    BMJ; 2013 Apr; 346():f2810. PubMed ID: 23633224
    [No Abstract]   [Full Text] [Related]  

  • 45. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
    Shen C; Zhao B; Liu L; Shih YT
    J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sticker shock.
    Nat Med; 2013 Jun; 19(6):653. PubMed ID: 23744133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral chemotherapy for colorectal cancer: some economic considerations.
    Saltz L
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):29-32. PubMed ID: 11219974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Economic Loss of Remaining Contents in Molecular Target Drug Preparation and the Simulation for Cost Saving].
    Usami E; Kimura M; Fukuoka T; Okada K; Yoshimura T
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):743-7. PubMed ID: 27306812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness.
    Messori A; Trippoli S; Vaiani M
    BMJ; 2002 Nov; 325(7375):1302; author reply 1302. PubMed ID: 12463189
    [No Abstract]   [Full Text] [Related]  

  • 50. [Anticancer agents: has the maximal tolerated price been reached?].
    Levêque D
    Bull Cancer; 2012 Sep; 99(9):808-10. PubMed ID: 22743187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics].
    Koinuma N
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):809-18. PubMed ID: 27431625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drug Vial Optimization(DVO)for Anti-Cancer Drugs].
    Iwamoto T
    Gan To Kagaku Ryoho; 2017 May; 44(5):353-356. PubMed ID: 28536326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Verification of reduction in preparation time and cost of cyclophosphamide when using the closed-system drug transfer device].
    Ikeno Y; Arii D; Nakajima H; Murooka K; Nojima M; Kidokoro A
    Gan To Kagaku Ryoho; 2014 May; 41(5):611-5. PubMed ID: 24917007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Examination of Actual Medical Material Cost and Cost Reduction Related to Exposure Prevention in the Preparation of Anticancer Drugs].
    Moriya A; Usami E; Hirose T; Takenaka S; Asano H; Okada K; Adachi S; Yoshimura T
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1281-1286. PubMed ID: 31501370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pricing and Value of Cancer Drugs.
    Burkholder R
    JAMA Oncol; 2015 Sep; 1(6):841-2. PubMed ID: 26355865
    [No Abstract]   [Full Text] [Related]  

  • 56. The exorbitant price of cancer drugs.
    Prescrire Int; 2012 Jul; 21(129):195. PubMed ID: 22852296
    [No Abstract]   [Full Text] [Related]  

  • 57. Alternative pricing strategies for cancer drugs.
    Messori A; De Rosa M; Pani L
    JAMA; 2015 Feb; 313(8):857. PubMed ID: 25710668
    [No Abstract]   [Full Text] [Related]  

  • 58. Alternative pricing strategies for cancer drugs--reply.
    Bach PB
    JAMA; 2015 Feb; 313(8):858. PubMed ID: 25710670
    [No Abstract]   [Full Text] [Related]  

  • 59. Economic comments on proposal for a novel cancer drug pricing model.
    Nuijten MJC; Vis J
    Nat Rev Clin Oncol; 2018 Sep; 15(9):587. PubMed ID: 30104696
    [No Abstract]   [Full Text] [Related]  

  • 60. Reply to 'Economic comments on proposal for a novel cancer drug pricing model'.
    Uyl-de Groot CA; Löwenberg B
    Nat Rev Clin Oncol; 2018 Sep; 15(9):588. PubMed ID: 30104695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.